Le Lézard
Classified in: Health
Subject: FDA

Sekisui Diagnostics Announces FDA Clearance and CLIA Waiver of the Acucytm Influenza A&B Test


BURLINGTON, Mass., Oct. 8, 2019 /PRNewswire/ -- Sekisui Diagnostics announces the Acucy Influenza A&B Test has received 510(k) clearance as a Class II assay from the US Food and Drug Administration (FDA), as well as, CLIA Waiver (Clinical Laboratory Improvement Amendments) for use on the Acucy Reader.

Acucy Influenza A&B Test

The Acucy Influenza A&B Test is intended for the rapid, qualitative detection of influenza A and B viral nucleoprotein antigens from both nasal and nasopharyngeal swabs. The combination of the Influenza A&B Test and the Reader provides clinicians with standardized and definitive result interpretation. Utilizing the Acucy Reader in either the point-of-care or laboratory setting provides workflow flexibility with Read Now and Walk Away features.

The addition of the Acucy Influenza A&B test expands Sekisui Diagnostics flu portfolio to include all three commonly used modalities in the CLIA Waived environment:  OSOM® Ultra Flu A&B Test (manual read lateral flow), Acucy Influenza A&B Test (point-of-care reader) and the Silaris® Influenza A&B Test (molecular point-of-care). Sekisui Diagnostics now offers options to address the varying needs of the market to help improve patient outcomes, maximize clinical efficiencies, and reduce operational budgets.

"This is a very exciting time for Sekisui Diagnostics.  The launch of the Acucy Influenza A&B Test makes us the first and only company to provide the three most commonly used flu testing methods in a CLIA Waived format.  We take great pride in listening to our customers and we understand they have different needs during flu season.  We remain committed to providing innovative, high quality testing options so they can make the right choice for their practices and patients," said Robert Schruender, President /CEO of Sekisui Diagnostics. "Accurate diagnosis of influenza is critical to minimize transmission of infection and we are proud to be able to provide sensitive and specific tools to healthcare professionals."

Testing patients provides valuable information to the clinician that can enable them to rule out other illnesses, help determine treatment and reduces the risk of prescribing unnecessary antivirals or antibiotics. Since the introduction of rapid molecular tests and the 2018 FDA Flu reclassification focusing on the improved performance of on market rapid immunoassays, clinicians are now more confident in test results and therefore better able to provide direct therapy.

About Sekisui Diagnostics:

Sekisui Diagnostics is a global diagnostics company committed to improving patients' lives by providing innovative medical diagnostics to physicians and laboratories through a global commercial network.  Product lines include clinical chemistry and coagulation systems, reagents, rapid test kits and point-of-care systems as well as enzymes and specialty bio-chemicals.

Sekisui Diagnostics Logo (PRNewsFoto/Sekisui Diagnostics) (PRNewsFoto/Sekisui Diagnostics)

SOURCE Sekisui Diagnostics


These press releases may also interest you

at 23:29
Viatris Inc. and Biocon Biologics Ltd. (a subsidiary of Biocon Ltd.) today announced that the U.S. Food and Drug Administration (FDA) has approved Semglee® (insulin glargine-yfgn injection) as the first interchangeable biosimilar product under the...

at 23:22
Nuvalent, Inc., a biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the pricing of its initial public offering of 9,750,000 shares of common stock, consisting of...

at 23:00
BioVaxys Technology Corp. ("BioVaxys" or the "Company") is pleased to announce that it has closed the second and final tranche of its previously announced non-brokered private placement (the "Private Placement")....

at 22:15
Icosavax, Inc. , a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases, today announced the...

at 22:15
A June 26 article on The U.S. Sun reports on what it sees as the widespread misuse of the tool most associated with dental hygiene: the toothbrush. The article notes that many brush their teeth too roughly, causing lasting damage to the enamel of...

at 21:15
Rallybio Corporation (Rallybio), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced the pricing of its initial...



News published on 8 october 2019 at 08:00 and distributed by: